Sichuan Kelun Pharmaceutical Co., Ltd. (SHE:002422)

China flag China · Delayed Price · Currency is CNY
32.20
+0.72 (2.29%)
At close: Feb 6, 2026
16.92%
Market Cap51.22B +17.8%
Revenue (ttm)18.30B -18.7%
Net Income1.67B -43.8%
EPS1.04 -45.0%
Shares Out1.59B
PE Ratio30.91
Forward PE27.82
Dividend0.63 (1.95%)
Ex-Dividend DateOct 21, 2025
Volume15,324,230
Average Volume13,813,424
Open31.41
Previous Close31.48
Day's Range31.38 - 32.98
52-Week Range26.72 - 41.72
Beta0.00
RSI54.30
Earnings DateApr 3, 2026

About SHE:002422

Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. It operates through Twinings, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-em... [Read more]

Sector Healthcare
Founded 1996
Employees 21,864
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 002422
Full Company Profile

Financial Performance

In 2024, SHE:002422's revenue was 21.81 billion, an increase of 1.67% compared to the previous year's 21.45 billion. Earnings were 2.94 billion, an increase of 19.53%.

Financial Statements

News

Crescent, Kelun-Biotech Sign Oncology Deal; Crescent To Raise $185 Mln; Stock Up

(RTTNews) - Crescent Biopharma, Inc. (CBIO), on Thursday announced an exclusive partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. to develop and commercialize oncology therapeutics, i...

2 months ago - Nasdaq